Restriction Endonucleases Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Market is Segmented by Type (Type I, Type II, Type III, Type IV), Application, End User, and Geography.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The restriction endonucleases market is expected to register a CAGR of nearly 4.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the usage of restriction endonuclease enzymes in various applications, like cloning, sequencing, and restriction digestion. Furthermore, the increasing funding and investment by biotechnology and pharmaceutical companies. According to a report by Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder, the pharmaceutical industry is a worldwide top investor in R&D today, and it is predicted that it will keep its role as a leading R&D stakeholder in the future, with an industry-wide forecasted total R&D spend of USD 160 billion by 2020. However, high cost of the production of restriction endonucleases is the drawback of the market growth.

Scope of the Report

As per the scope of the report, restriction endonuclease is an enzyme that cuts the DNA molecule at, or near to, a specific nucleotide sequence to produce discrete DNA fragments that can be separated by gel electrophoresis. This report is segmented by type, application, end user, and geography.

By Type
Type I
Type II
Type III
Other Types
By Application
Genetic Engineering
DNA Mapping
Gene Sequencing
Other Applications
By End User
Pharmaceutical and Biotechnology Companies
Academic Research Institutes
Other End Users
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East & Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Type II Segment is Dominating the Restriction Endonucleases Market

Type II restriction enzymes are the familiar ones used for everyday molecular biology applications, such as gene cloning and DNA fragmentation and analysis. These enzymes cleave DNA at fixed positions with respect to their recognition sequence, creating reproducible fragments and distinct gel electrophoresis patterns. Over 3,500 Type II enzymes have been discovered and characterized, recognizing some 350 different DNA sequences. Type II restriction endonucleases always cleave at or near their recognition sites. They produce small, well-defined fragments of DNA that help to characterize genes and genomes and that produce recombinant DNAs. As the Type II enzymes are the most used and more advantageous, the segment has the maximum share. Furthermore, the other factors propelling the segment growth are increasing investments in research and development by biotechnology and pharmaceutical companies.

Restr Endo

North America Dominates the Market, and It is Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors, such as the presence of key players, high investments, and growing research and development programs in the field of biotechnology, pharmaceuticals in the region, and established healthcare infrastructure. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth.

Restriction Endonucleases

Competitive Landscape

The restriction endonucleases market is moderately competitive and consists several major players. Some of the companies that are currently dominating the market are Agilent Technologies, Thermo Fisher Scientific, Illumina Inc., New England Biolabs, Merck KGaA, Promega Corporation, Takara Bio Inc., and QIAGEN NV.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Use of Restriction Endonucleases in Various Applications

      2. 4.2.2 Increasing Expenditure on Research and Development by Biotechnology and Pharmaceutical Companies.

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Restriction Endonucleases Production

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Type I

      2. 5.1.2 Type II

      3. 5.1.3 Type III

      4. 5.1.4 Other Types

    2. 5.2 By Application

      1. 5.2.1 Genetic Engineering

      2. 5.2.2 DNA Mapping

      3. 5.2.3 Gene Sequencing

      4. 5.2.4 Other Applications

    3. 5.3 By End User

      1. 5.3.1 Pharmaceutical and Biotechnology Companies

      2. 5.3.2 Academic Research Institutes

      3. 5.3.3 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Agilent Technologies

      2. 6.1.2 Thermo Fisher Scientific

      3. 6.1.3 Illumina Inc.

      4. 6.1.4 New England Biolabs

      5. 6.1.5 Merck KGaA

      6. 6.1.6 Promega Corporation

      7. 6.1.7 Takara Bio Inc.

      8. 6.1.8 QIAGEN NV

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Restriction Endonucleases Market market is studied from 2018 - 2026.

The Restriction Endonucleases Market is growing at a CAGR of 4.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Agilent Technologies, Thermo Fisher Scientific, Illumina, Inc., New England Biolabs, Merck KGaA are the major companies operating in Restriction Endonucleases Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!